• Shanghai Junshi Biosciences' Oct. 28, 2026, announcement confirms China's regulator converted toripalimab's advanced urothelial carcinoma approval from conditional to regular.
• The monotherapy indication covers locally advanced or metastatic disease following failed platinum-containing chemotherapy, including progression within 12 months of neoadjuvant or adjuvant treatment.
• Toripalimab initially received conditional approval in April 2021; the conversion primarily relied on results from the Phase III RC48-C016 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12386657), on October 28, 2026, and is solely responsible for the information contained therein.